{"Clinical Trial ID": "NCT01009918", "Intervention": ["INTERVENTION 1:", "The arm I Lisinopril", "Patients receive lisinopril orally once daily.", "Lisinopril: given orally", "INTERVENTION 2:", "Bras II Coreg CR\u00ae", "Patients receive Coreg CR\u00ae orally once daily.", "Coreg CR\u00ae: Oral data"], "Eligibility": ["INDUSTRIAL CRITERIA", "\u00b7 18-year-old men and women with positive HER2 breast cancer", "The treatment with trastuzumab (Herceptin\u00ae) may be administered with or after primary chemotherapy. Trastuzumab (Herceptin\u00ae) may be used in combination with trastuzumab.", "- Left ventricular ejection fraction (LVEF) 50% by MUGA scan or echocardiogram", "adequate renal function for the administration of chemotherapy treatment containing trastuzumab.", "Systolic blood pressure sitting > 90 mm Hg", "- Poultry 60 beats/minute", "No pregnancy or breast-feeding", "Women of childbearing potential, who are sexually active, must undergo a negative pregnancy test before starting the study.", "Both men and women should be prepared to use effective contraception during the study. Teratogenicity is documented for both active agents in the study.", "\u2022 Capable of swallowing capsules", "EXCLUSION CRITERIA:", "Patients with metastatic disease", "Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy", "Current treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor inhibitors (ARBs), such as losartan, \u03b2-blockers or digoxin", "Known cardiac history: heart failure, myocardial infarction, radio-induced cardiac dysfunction", "A known allergy to ACE inhibitors or \u03b2-blockers", "\u2022 History of bronchial asthma or related bronchospastic conditions", "Angioedema hereditary or idiopathic", "\u2022 History of severe hypersensitivity reactions to medicines or other causes, i.e. bee bites", "This protocol does not exclude patients who are involved in other research studies. Refer to the IRB's local guidelines."], "Results": ["Performance measures:", "Number of participants with trastuzumab-induced cardiotoxicity after 52 weeks of treatment", "- Decreased incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment, as measured by the preservation of the left ventricular ejection fraction (LVEF).", "Time limit: 2 years", "Results 1:", "Title of arm/group: Arm I Lisinopril", "Description of the arm/group: Patients receive lisinopril orally once daily.", "Lisinopril: given orally", "Total number of participants analysed: 152", "Type of measure: Number of participants", "Unit of measure: Participants 45 29.6%", "Results 2:", "Title of arm/group: Arm II Coreg CR", "Description of the arm/group: Patients receive Coreg CR orally once daily.", "Coreg CR: Oral data", "Total number of participants analysed: 147", "Type of measure: Number of participants", "Unit of measure: Participants 43 29.3%"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/158 (3.16 per cent)", "Anemia 1/158 (0.63%)", "Febrile Neutropenia 0/158 (0.00 %)", "- Spleen disorder 0/158 (0.00 %)", "Palpitations 0/158 (0.00 %)", "Chest pain - heart 0/158 (0.00 %)", "Pericardial infusion 1/158 (0.63%)", "- Collision 0/158 (0.00 %)", "Diarrhoea 1/158 (0.63%)", "- Fatigue 0/158 (0.00 %)", "Skin infection 0/158 (0.00 %)", "Decrease in neutrophil count 0/158 (0.00 %)", "Adverse Events 2:", "Total: 4/156 (2.56%)", "Anemia 0/156 (0.00 per cent)", "Febrile Neutropenia 1/156 (0.64%)", "- Spleen disorder 0/156 (0.00 per cent)", "- Palpitations 0/156 (0.00 per cent)", "Cardiac chest pain 0/156 (0.00 %)", "Pericardial infusion 0.156 (0.00 %)", "- Collision 1/156 (0.64 per cent)", "Diarrhoea 0/156 (0.00 per cent)", "Fatigue 1/156 (0.64%)", "- Skin infection 0/156 (0.00 %)", "Decrease in neutrophil count 1/156 (0.64%)"]}